• Muhammet Kocabaş, Yakup Alsancak, Mustafa Can, İlker Çordan, BurgucuHatice ÇalışkanHÇDivision of Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey., Melia Karaköse, Fatma Hümeyra Yerlikaya, Mustafa Kulaksızoğlu, and Feridun Karakurt.
• Division of Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey.
• Turk J Med Sci. 2022 Aug 1; 52 (4): 103310401033-1040.

BackgroundData on the presence and extent of cardiovascular disease (CVD) risk in primary hyperparathyroidism (PHPT) are conflicting. In our study, we aimed to investigate the increased CVD risk in patients with PHPT by carotid intima-media thickness (CIMT), epicardial adipose tissue (EAT) thickness, and serum levels of endocan and nesfatin-1.MethodsPatients with PHPT (n = 44) and age- and sex-matched healthy control subjects (n = 40) were enrolled in this study. Demographic data of the participants were questioned. Serum endocan and nesfatin-1 concentrations were assessed using commercially available ELISA kits. Noninvasive measurements of CIMT and EAT thickness were made with high-resolution ultrasonography and B-mode echocardiography.ResultsThere was no statistically significant difference in serum endocan and nesfatin-1 levels and EAT thickness in the PHPT group compared to controls. CIMT was statistically significantly higher in the PHPT group compared to controls (p = 0.001). A negative correlation was found between PTH and low-density lipoprotein cholesterol level (p = 0.001) but no significant relationship was found between other parameters.DiscussionWe found that CIMT is increased in patients with PHPT and consequently, CVD risk is high in these patients. More comprehensive studies are needed to identify other markers that predict increased CVD risk in patients with PHPT.

17 keywords...

hide…